

Ofrecer respuestas para la EPOC (Enfermedad pulmonar obstructiva crónica): Estrategias prácticas para mejorar el diagnóstico temprano y el tratamiento centrado en el paciente en atención primaria: Identificación, diagnóstico y evaluación temprana de la EPOC – Tweetorial #1

Referencias

Tweet 5

Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. *Lancet Respir Med*. 2017;5(5):426-434. doi:10.1016/S2213-2600(17)30119-4

Çolak Y, Afzal S, Nordestgaard BG, Lange P, Vestbo J. Importance of early COPD in young adults for development of clinical COPD. Findings from the Copenhagen General Population Study. *Am J Respir Crit Care Med*. 2021;203(10):1245-1256. doi:10.1164/rccm.202003-0532OC

GOLD. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2022 Report. Global Initiative for Chronic Obstructive Lung Disease; 2022.

Tweet 6

Natali D, Cloatre G, Hovette P, Cochrane B. Screening for comorbidities in COPD. *Breathe (Sheff)*. 2020;16(1):190315. doi:10.1183/20734735.0315-2019

Tzovaras NZ, Kouloumenta VN, Gourgoulisanis KI. The economic impact of late detection of COPD in general practice. *Chest*. 2005;127:412; author reply 412-413. doi:10.1378/chest.127.1.412

Tweet 7

Larsson K, Janson C, Ställberg B, et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. *Int J Chron Obstruct Pulmon Dis*. 2019;14:995-1008. doi:10.2147/COPD.S195382

Tweet 9

Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med*. 2005;142(4):233-239. doi:10.7326/0003-4819-142-4-200502150-00005

Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. *COPD*. 2010;7(5):375-382. doi:10.3109/15412555.2010.510160

Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ*. 2000;320(7425):1297-1303. doi:10.1136/bmj.320.7245.1297

Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. *Respir Med*. 2006;100(1):115-122. doi:10.1016/j.rmed.2005.03.035.

McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, for the TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax*. 2007;62(5):411-415. doi:10.1136/thx.2006.072348

Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. *N Engl J Med*. 1999;340(25):1948-1953. doi:10.1056/NEJM19990624340250

Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? *Eur Respir Rev*. 2018;27(149):180057. doi:10.1183/16000617.0057-2018

Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med*. 2008;359:1543-1554. doi:10.1016/j.arbres.2012.04.001

Tweets 14 and 15

IPCRG Desktop Helper: Early diagnosis of COPD does help! November 17, 2009. Accessed June 1, 2022. <https://www.ipcr.org/dtheearlydiagcopd>

Tweet 17

IPCRG Desktop Helper: Spirometry. March 2010. Accessed June 1, 2022. Available at: https://www.ipcr.org/sites/ipcr/files/content/attachments/2020-03-04/IPCRG_Desktop_Helper_Spirometry.pdf

Tweets 18 and 19

Eschenbache W. Airflow limitation and spirometry. In: Panos RJ, ed. *COPD Clinical Perspectives*. IntechOpen. 2011.

Tweet 21

IPCRG Desktop Helper: Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). May 2020. Accessed March 2, 2022. <https://www.ipcr.org/sites/ipcr/files/content/attachments/2020-06-02/IPCRG%20DH6%20ICS%20COPD%20Rev%20May20.pdf>

GOLD. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2022 Report. Global Initiative for Chronic Obstructive Lung Disease; 2022.

Miravittles M, Soler-Cataluña SS, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. *Arch Bronconeumol*. 2012;48(7):247-257. doi:10.1016/j.arbres.2012.04.001

Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. an official american thoracic society clinical practice guideline. *Am J Respir Crit Care Med*. 2020;201(9):e56-e69. doi:10.1164/rccm.202003-0625ST